Aisling Murphy, Janssen Sciences Ireland demonstrating the technology used at the facility to Martin Shanahan, Chief Executive of IDA Ireland, Minister for Public Expenditure & Reform, Michael McGrath, Gary Hartnett, General Manager of Janssen Sciences Ireland, and Leila Schwery-Bou-Diab, VP, Manufacturing & Technical Operation at Johnson & Johnson. Photo: Michael O’Sullivan/OSM PHOTO

‘Really fantastic news for Cork’

The €150m investment by Janssen Sciences Ireland, part of Johnson & Johnson, will add to its existing global manufacturing capacity, allowing the company to reach patients with crucial biomedicines faster.

Construction on the expansion started this year and is expected to take two years to complete. Up to 300 people will be employed during the construction period.

An Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar said: “This is really fantastic news for Cork and for patients across the world who use the medicines made here. I’m really proud of Ireland’s thriving life sciences sector. Investment like this demonstrates the strength of talent we have here.”

Operating in Ringaskiddy since 2005, the Janssen site manufactures medicines for immunology and oncology patients, addressing critical needs in areas such as rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis and multiple myeloma.

Leila Schwery-Bou-Diab, Vice President Manufacturing and Technical Operation, Johnson & Johnson said: “The additional manufacturing capacity created by this investment will enhance the work we do to deliver transformational medicines that can change the trajectory of health. Every day, over 40,000 of our Janssen colleagues are working tirelessly to create a better future for our patients by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.”

This investment project will create new roles in the areas of facilities, engineering, quality, manufacturing and regulatory affairs. The company currently has a workforce of more than 700 people at the Ringaskiddy site.

Gary Hartnett, General Manager, Janssen Sciences said: “We will be adding 180 potential new roles as part of this announcement. It is an incredible opportunity to join a diverse workforce made up of the best and brightest minds.”

The announcement follows a €300m investment in 2017, which saw the construction of a large scale manufacturing suite at the Ringaskiddy site.